financetom
Forex World Market Business Cryptocurrency Commodities MAP
financetom
Business
financetom
/
Business
/
Keros Therapeutics Voluntarily Halts Phase 2 Trial for Cibotercept Over Pericardial Effusion Concerns; Shares Drop Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Keros Therapeutics Voluntarily Halts Phase 2 Trial for Cibotercept Over Pericardial Effusion Concerns; Shares Drop Pre-Bell
Jan 15, 2025 5:24 AM

08:02 AM EST, 01/15/2025 (MT Newswires) -- Keros Therapeutics ( KROS ) said Wednesday it has voluntarily halted all dosing in its phase 2 TROPOS trial for cibotercept in patients with pulmonary arterial hypertension due to "new observations of pericardial effusion adverse events."

The decision includes all treatment arms, including the 1.5 mg/kg and placebo groups.

Keros Therapeutics ( KROS ) halted higher dose treatments of 3.0 mg/kg and 4.5 mg/kg last December due to similar concerns.

Keros Therapeutics ( KROS ) shares were down more than 16% in recent premarket activity.

Price: 10.39, Change: -2.09, Percent Change: -16.75

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Teamshares to Go Public in US Under $746 Million Deal With Live Oak Acquisition
Market Chatter: Teamshares to Go Public in US Under $746 Million Deal With Live Oak Acquisition
Nov 14, 2025
08:37 AM EST, 11/14/2025 (MT Newswires) -- Teamshares has decided to go public in the US through Live Oak Acquisition (LOKV) under a $746 million blank-check agreement, Reuters reported Friday, citing Teamshares Chief Executive Michael Brown. The transaction is anticipated to generate up to $333 million in proceeds, including a $126 million private investment in public equity anchored by T....
 Form 8.3
Form 8.3
Nov 14, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Arrowstreet Capital, Limited Partnership (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
 ETHZilla Names John Saunders as CFO
ETHZilla Names John Saunders as CFO
Nov 14, 2025
08:37 AM EST, 11/14/2025 (MT Newswires) -- ETHZilla ( ETHZ ) said Friday it has named John Saunders as chief financial officer and senior vice president, effective the first business day after the filing of the company's quarterly report. Saunders previously served as the company's vice president of finance, the company said. Shares of the company were down over 5%...
 CG Oncology Q3 Net Loss Widens; Revenue Rises
CG Oncology Q3 Net Loss Widens; Revenue Rises
Nov 14, 2025
08:34 AM EST, 11/14/2025 (MT Newswires) -- CG Oncology ( CGON ) reported a Q3 net loss Friday of $0.57 per diluted share, widening from a loss of $0.30 a year earlier. Analysts surveyed by FactSet expected a loss of $0.57 per share. Revenue for the quarter ended Sept. 30 was $1.7 million, compared with $43,000 a year earlier. Analysts...
About
Terms and Conditions Privacy policy Cookie Settings Contact Us
Services
Login register
financetom Market Personal Finance Business Economy Cryptocurrency MAP
Links
zpostcode Recruit weather mreligion Yellowpages sport constellation shopping name game directory literature Word tour furnish Lottery tftnews lyrics News digital car dir Edu Finance
Copyright 2023-2026 - www.financetom.com All Rights Reserved